Reports
Sale
Anti-Obesity Drugs Market Size, Share, Analysis, Forecast: By Drugs: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Others; By Drug Class; By Mechanism of Action; By Route of Administration; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Anti-Obesity Drugs Market Outlook
The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, driven by the rising prevalence of obesity across the 8 major markets. The market is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to rise from USD 2.8 billion in 2024 to USD 6.3 billion by 2032.
Key Takeaways
- According to the World Obesity Atlas 2023 report, around 38% of the global population falls in the overweight or obese category.
- In December 2023, F. Hoffmann-La Roche AG announced its plan to acquire Carmot Therapeutics for USD 2.7 billion to gain access to Carmot’s anti-obesity drug candidate, CT-388.
- Novo Nordisk A/S and Eli Lilly with their anti-obesity drugs Wegovy and Zepbound, respectively, dominate the market segment.
Anti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.
The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing funding in obesity-related research. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market landscape.
Anti-Obesity Drugs Market Trends and Developments
The growing focus on combination therapies, heightened patient awareness, regulatory support, and increased use of GLP-1 receptor agonists comprise some of the key trends and developments in the market.
| Date | Company | Event |
| November 2023 | Novo Nordisk A/S | The leading pharmaceutical company invested USD 2.3 billion in an existing French production facility to expand capacity for the manufacturing of drug candidates such as anti-obesity semaglutide medication (marketed as Wegovy). |
| November 2023 | AstraZeneca | AstraZeneca invested up to USD 185 million upfront and USD 1.825 billion on milestones in the anti-obesity drug market by licensing an experimental oral drug ECC5004 from Eccogene (a Chinese biopharmaceutical company) that showed potential for fewer side effects. Through Eccogene's drug, the company aims to compete with injectable weight loss treatments like Wegovy. |
| November 2023 | Eli Lilly | Eli Lilly and Company announced the United States Food and Drug Administration (FDA) approval for Zepbound™ (tirzepatide) injection, a novel treatment for chronic weight management. The company revealed that Zepbound is the only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. |
| Key Trend | Impact |
| Increased Focus on Combination Therapies | There is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional monotherapies. |
| Heightened Patient Awareness | There is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market demand. |
| Regulatory Support | Regulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical trials. |
| Increased Use of GLP-1 Receptor Agonists | Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss. |
Factors Influencing Anti-Obesity Drugs Market Growth
The market is driven by the rising prevalence of obesity which makes the individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. Recent data suggests that the global overweight and obesity prevalence is expected to reach 51% by 2035 , which reflects the necessity for effective and affordable anti-obesity drugs in the market. Moreover, increasing focus on research in obesity management has resulted in advancements in drug development technologies, which are expected to fuel the anti-obesity drugs market size in the forecast period.
One of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth.
Anti-Obesity Drugs Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Drugs | Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide |
| Drug Class | Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor |
| Mechanism of Action | Centrally Acting Drugs, Peripherally Acting Drugs |
| Route of Administration | Oral, Subcutaneous |
| Prescription Type | Prescription Drugs, Over the Counter Drugs |
| Distribution Channel | Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies |
| Region | United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, India |
By drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. The rising prevalence of obesity is expected to fuel the anti-obesity drugs market value.
The market segmentation by drug class comprises amphetamines, GLP-1 receptor agonists, and lipase inhibitors. This market segment represents different pharmacological approaches to combating obesity.
In terms of mechanism of action, anti-obesity drugs can be categorized as centrally acting drugs or peripherally acting drugs, indicating their site of action within the body.
The route of administration segment includes oral and subcutaneous administration methods. This market segment offers distinct options to take drugs, depending on patient convenience and treatment regimen.
By prescription type, the anti-obesity drugs market share includes prescription drugs and over-the-counter drugs. This market segment is based on whether the drugs require a healthcare provider's authorization for purchase.
Distribution channels for anti-obesity drugs are hospital pharmacies, drug store and retail pharmacies, along with online pharmacies, catering to diverse patient needs and preferences.
Geographically, the market report includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. Each region contributes distinctly to the overall dynamics of the anti-obesity drugs market depending on certain variables such as regulatory framework, prevalence of obesity, and the status of healthcare facilities.
Anti-Obesity Drugs Market: Competitive Landscape
The key market players are contributing to the anti-obesity drugs market growth through strategic mergers and acquisitions initiatives, novel product launches, and continuous research and development efforts aimed at technological advancement.
| Company | Year Founded | Headquarters | Products/Services |
| GlaxoSmithKline PLC | 2000 | Brentford, United Kingdom | Offers a range of pharmaceutical products, including anti-obesity drugs such as Orlistat (Alli) |
| Novo Nordisk A/S | 1923 | Bagsværd, Denmark | Specializes in diabetes care and other serious chronic conditions, offering anti-obesity drugs like Wegovy |
| Vivus LLC | 1991 | Campbell, California, USA | Specializes in the development and commercialization of novel therapeutic products, including Qsymia for obesity treatment. |
| Currax Pharmaceuticals LLC | 2019 | Brentwood, Tennessee, United States | Offers a portfolio of pharmaceutical products, including Contrave for weight management and obesity treatment. |
Other key players in the market include Pfizer Inc., Rhythm Pharmaceuticals, KVK Tech Inc., CHEPLAPHARM Arzneimittel GmbH, Gelesis Holding Inc., Boehringer Ingelheim International GmbH, and Eli Lilly and Company among others.
Anti-Obesity Drugs Market Analysis by Region
In North America, the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market demand.
Europe also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Route of Administration |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Anti-Obesity Drugs Market Overview – 8 Major Markets
3.1 Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 Obesity Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Anti-Obesity Drugs Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Obesity Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Obesity Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Obesity Epidemiology Scenario and Forecast (2017-2032)
6.5 India Obesity Epidemiology Scenario and Forecast (2017-2032)
7 Anti-Obesity Drugs Market Landscape – 8 Major Markets
7.1 Anti-Obesity Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anti-Obesity Drugs: Product Landscape
7.2.1 Analysis by Prescription Type
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Drug Class
7.2.4 Analysis by Mechanism of Action
7.2.5 Analysis by Route of Administration
8 Anti-Obesity Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Anti-Obesity Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Anti-Obesity Drugs Market Segmentation (2017-2032) - 8 Major Markets
11.1 Anti-Obesity Drugs Market (2017-2032) by Drugs
11.1.1 Market Overview
11.1.2 Semaglutide
11.1.3 Phentermine/Topiramate
11.1.4 Naltrexone/Bupropion
11.1.5 Liraglutide
11.1.6 Gelesis 100
11.1.7 Orlistat
11.1.8 Phentermine
11.1.9 Methamphetamine
11.1.10 Tirzepatide
11.2 Anti-Obesity Drugs Market (2017-2032) by Drug Class
11.2.1 Market Overview
11.2.2 Amphetamine
11.2.3 GLP-1 receptor agonist
11.2.4 Lipase Inhibitor
11.3 Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
11.3.1 Market Overview
11.3.2 Centrally Acting Drugs
11.3.3 Peripherally Acting Drugs
11.4 Anti-Obesity Drugs Market (2017-2032) by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Subcutaneous
11.5 Anti-Obesity Drugs Market (2017-2032) by Prescription Type
11.5.1 Market Overview
11.5.2 Prescription Drugs
11.5.3 Over The Counter Drugs
11.6 Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Drug Store & Retail Pharmacies
11.6.4 Online Pharmacies
11.7 Anti-Obesity Drugs Market (2017-2032) by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
11.7.5 India
12 United States Anti-Obesity Drugs Market (2017-2032)
12.1 United States Anti-Obesity Drugs Market Historical Value (2017-2023)
12.2 United States Anti-Obesity Drugs Market Forecast Value (2024-2032)
12.3 United States Anti-Obesity Drugs Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Semaglutide
12.3.3 Phentermine/topiramate
12.3.4 Naltrexone/bupropion
12.3.5 Liraglutide
12.3.6 Gelesis 100
12.3.7 Orlistat
12.3.8 Phentermine
12.3.9 Methamphetamine
12.3.10 Tirzepatide
12.4 United States Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
12.4.1 Market Overview
12.4.2 Centrally Acting Drugs
12.4.3 Peripherally Acting Drugs
13 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032)
13.1 EU-4 and United Kingdom Anti-Obesity Drugs Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Anti-Obesity Drugs Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Anti-Obesity Drugs Market Overview
13.4 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Type
13.4.1 Market Overview
13.4.2 Semaglutide
13.4.3 Phentermine/topiramate
13.4.4 Naltrexone/bupropion
13.4.5 Liraglutide
13.4.6 Gelesis 100
13.4.7 Orlistat
13.4.8 Phentermine
13.4.9 Methamphetamine
13.4.10 Tirzepatide
13.5 EU-4 and United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
13.5.1 Market Overview
13.5.2 Centrally Acting Drugs
13.5.3 Peripherally Acting Drugs
14 Japan Anti- Obesity Drugs Market
14.1 Japan Anti-Obesity Drugs Market Historical Value (2017-2023)
14.2 Japan Anti-Obesity Drugs Market Forecast Value (2024-2032)
14.3 Japan Anti-Obesity Drugs Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Semaglutide
14.3.3 Phentermine/topiramate
14.3.4 Naltrexone/bupropion
14.3.5 Liraglutide
14.3.6 Gelesis 100
14.3.7 Orlistat
14.3.8 Phentermine
14.3.9 Methamphetamine
14.3.10 Tirzepatide
14.4 Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
14.4.1 Market Overview
14.4.2 Centrally Acting Drugs
14.4.3 Peripherally Acting Drugs
15 India Anti- Obesity Drugs Market
15.1 India Anti-Obesity Drugs Market (2017-2032) Historical Value (2017-2023)
15.2 India Anti-Obesity Drugs Market (2017-2032) Forecast Value (2024-2032)
15.3 India Anti-Obesity Drugs Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Semaglutide
15.3.3 Phentermine/topiramate
15.3.4 Naltrexone/bupropion
15.3.5 Liraglutide
15.3.6 Gelesis 100
15.3.7 Orlistat
15.3.8 Phentermine
15.3.9 Methamphetamine
15.3.10 Tirzepatide
15.4 India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
15.4.1 Market Overview
15.4.2 Centrally Acting Drugs
15.4.3 Peripherally Acting Drugs
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 GlaxoSmithKline PLC
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Pfizer Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Novo Nordisk A/S
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Rhythm Pharmaceuticals
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 KVK Tech Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Currax Pharmaceuticals LLC
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 CHEPLAPHARM Arzneimittel GmbH
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Vivus LLC
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Gelesis Holding Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Boehringer Ingelheim International GmbH
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Eli Lilly and Company
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
List not exhaustive
23 Anti-Obesity Drugs Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 2.5 billion in 2023 driven by the rising prevalence of obesity across the 8 major markets.
The market is anticipated to grow at a CAGR of 10.7% during the forecast period of 2024-2032, likely to reach a market value of USD 6.3 billion by 2032.
The market demand is driven by heightened patient awareness, increasing healthcare investments along with rising disposable incomes.
One of the significant trends in the market is the surge in drug approvals from the health regulatory bodies. In November 2023, Eli Lilly and Company announced the United States FDA approval for Zepbound™ (tirzepatide) injection, a novel treatment for chronic weight management.
Based on the drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.
Based on the drug class, the market is segmented into Amphetamine, GLP-1 receptor agonist, and Lipase Inhibitors.
Mechanisms of action include centrally acting drugs and peripherally acting drugs.
Various routes of administration for anti-obesity drugs are oral and subcutaneous.
Based on the prescription type, the market is segmented into prescription drugs and over-the-counter drugs.
Distribution channels in the market include hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India.
Key players involved in the market are GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk A/S, Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., and Boehringer Ingelheim International GmbH.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER